

# Michael T Barrett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5098678/publications.pdf>

Version: 2024-02-01

26  
papers

1,982  
citations

430874

18  
h-index

580821

25  
g-index

26  
all docs

26  
docs citations

26  
times ranked

4058  
citing authors

#	ARTICLE	IF	CITATIONS
1	Synergistic combination of cytotoxic chemotherapy and cyclinâ€dependent kinase 4/6 inhibitors in biliary tract cancers. <i>Hepatology</i> , 2022, 75, 43-58.	7.3	6
2	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3797-3805.	2.3	4
3	Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. <i>JCO Precision Oncology</i> , 2022, , .	3.0	11
4	Unique evolutionary trajectories of breast cancers with distinct genomic and spatial heterogeneity. <i>Scientific Reports</i> , 2021, 11, 10571.	3.3	0
5	Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer. <i>JAMA Oncology</i> , 2020, 6, 125.	7.1	53
6	Unique genomic and neoepitope landscapes across tumors: a study across time, tissues, and space within a single lynch syndrome patient. <i>Scientific Reports</i> , 2020, 10, 12190.	3.3	3
7	Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas. <i>Cancer Research</i> , 2020, 80, 4324-4334.	0.9	36
8	Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 1063-1078.	2.3	14
9	Clonal analyses of refractory testicular germ cell tumors. <i>PLoS ONE</i> , 2019, 14, e0213815.	2.5	17
10	Exploring the spatiotemporal genetic heterogeneity in metastatic lung adenocarcinoma using a nuclei flowâ€sorting approach. <i>Journal of Pathology</i> , 2019, 247, 199-213.	4.5	8
11	JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e1205-e1215.	2.4	46
12	The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers. <i>Breast Cancer Research</i> , 2018, 20, 71.	5.0	55
13	Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. <i>British Journal of Cancer</i> , 2017, 117, 572-582.	6.4	26
14	Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification. <i>Modern Pathology</i> , 2017, 30, 1516-1526.	5.5	22
15	Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. <i>Nature Communications</i> , 2015, 6, 7686.	12.8	393
16	Genomic amplification of 9p24.1 targeting <i>JAK2</i> , <i>PD-L1</i> , and <i>PD-L2</i> is enriched in high-risk triple negative breast cancer. <i>Oncotarget</i> , 2015, 6, 26483-26493.	1.8	118
17	Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 132.	2.0	65
18	Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma. <i>PLoS Genetics</i> , 2014, 10, e1004135.	3.5	292

#	ARTICLE	IF	CITATIONS
19	Chromosome-breakage genomic instability and chromothripsis in breast cancer. <i>BMC Genomics</i> , 2014, 15, 579.	2.8	49
20	STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. <i>Genome Medicine</i> , 2014, 6, 9.	8.2	23
21	Deep Clonal Profiling of Formalin Fixed Paraffin Embedded Clinical Samples. <i>PLoS ONE</i> , 2012, 7, e50586.	2.5	42
22	Advancing a clinically relevant perspective of the clonal nature of cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 12054-12059.	7.1	101
23	Molecular phenotype of spontaneously arising 4N (G2-tetraploid) intermediates of neoplastic progression in Barrett's esophagus. <i>Cancer Research</i> , 2003, 63, 4211-7.	0.9	52
24	Transcriptional Analyses of Barrett's Metaplasia and Normal Upper GI Mucosae. <i>Neoplasia</i> , 2002, 4, 121-128.	5.3	41
25	Evolution of neoplastic cell lineages in Barrett oesophagus. <i>Nature Genetics</i> , 1999, 22, 106-109.	21.4	409
26	p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. <i>Journal of Cutaneous Pathology</i> , 1998, 25, 291-296.	1.3	96